"There were situations where detailed electrograms were available on PURE EP™ and lacking on other systems. The PURE EP™ signals affect my decisions about PVC origin and optimal site of RF ablation.""
I know I harp on it it, but this it the doctor discovering "I didn't know that I didn't know." And it often can only be realized while doing the procedure itself. So even if there is a determination that "only" 40% of the electrograms show valuable additional data because of using the PureEP system, that doesn't mean that they will only have a 40% opportunity of market penetration. All labs will want this. (Paying for it is another thing.)
It's why it is not farfetched to think a large device company will come knocking to see if they can acquire the tech usage exclusively for their own lab set-ups. And it is one reason Ken and team went ahead with the poison pill set-up (not just for Covid at the time). Value for the tech will continue to grow. No lowball offers will be accepted, imo.